Drug resistance in mutant FLT3-positive AML.

Oncogene
Ellen WeisbergJames D Griffin

Abstract

Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target for the therapy of AML. There are several FLT3 inhibitors presently in clinical trials with sufficient efficacy and toxicity features to warrant further testing in combination with standard therapies. However, the transient and partial responses observed in AML patients treated with FLT3 inhibitors, coupled with the discovery of drug-resistant leukemic blast cells in AML patients, have made resistance to FLT3 inhibitors a growing concern. In this study, we provide an overview of the role of mutant FLT3 in AML, FLT3 inhibitors under clinical and preclinical investigation, mechanisms of resistance to FLT3 inhibitors, and possible therapeutic approaches to overcoming this resistance.

References

Jul 1, 1996·European Journal of Haematology·I OlssonU Gullberg
Jan 1, 1996·Rapid Communications in Mass Spectrometry : RCM·M G Qian, D M Lubman
Jul 22, 1998·Molecular and Cellular Biology·M A MurphyD D Bowtell
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·M NaramuraH Gu
Sep 1, 1999·British Journal of Haematology·J F Dimartino, M L Cleary
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Apr 3, 2003·Bioorganic & Medicinal Chemistry·Aviv GazitAlexander Levitzki
Sep 3, 2003·Nature Reviews. Cancer·Mel F Greaves, Joe Wiemels
Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Feb 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·M Golam MohiBenjamin G Neel

❮ Previous
Next ❯

Citations

Apr 16, 2011·Leukemia·L S SteelmanJ A McCubrey
Oct 6, 2012·Leukemia·O H KrämerS K Knauer
Nov 5, 2013·Antioxidants & Redox Signaling·Aris T Alexandrou, Jian Jian Li
Aug 10, 2013·EMBO Molecular Medicine·Jung Eun ParkQi Zeng
Jan 1, 2014·Journal of Clinical Medicine·Caroline Benedicte Nitter EngenBjørn Tore Gjertsen
Sep 8, 2015·Bioorganic & Medicinal Chemistry Letters·Xing-Dong LinSheng-Yong Yang
Feb 9, 2011·Journal of Cellular Physiology·James A McCubreyAlberto M Martelli
Nov 14, 2015·Journal of Cellular Biochemistry·Rayapadi G SwethaAnand Anbarasu
Jan 22, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Sadaf ShahabTahir S Shamsi
Apr 10, 2013·European Journal of Medicinal Chemistry·Daphnie PauwelsJan Cools
Feb 15, 2014·Cancer Cell·Alexandre PuissantKimberly Stegmaier
Oct 23, 2016·Clinical Lymphoma, Myeloma & Leukemia·Mona HassaneinRiad El Fakih
Sep 1, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Xiao ChenZichun Hua
Jan 11, 2018·Cells·Riad El FakihMona Hassanein
Jan 17, 2020·The FEBS Journal·Panagiota S GeorgouliaRan Friedman
Feb 13, 2019·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Nichole Sly, Katie Gaspar
Jul 24, 2020·Oncology and Therapy·Alessandro FiorentiniAttilio Olivieri
Nov 15, 2018·Cancers·Mario LuppiAdriano Venditti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.